Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment

Cabaletta Bio, Inc. ((CABA)) announced an update on their ongoing clinical study.

RESET-MG is a Phase 1/2 clinical study conducted by Cabaletta Bio, Inc. to evaluate the safety and efficacy of CABA-201, an autologous CD19-specific chimeric antigen receptor T cell therapy, in participants with generalized myasthenia gravis (gMG). The study aims to assess the potential of CABA-201 to provide a new treatment option for this chronic autoimmune neuromuscular disorder, which currently has limited therapeutic solutions.

The intervention being tested is CABA-201, a biological treatment administered as a single intravenous infusion. This therapy is designed to target and potentially reduce the symptoms of gMG by utilizing genetically modified T cells that are specific to the CD19 antigen.

The study follows an interventional design with a single-group assignment, meaning all participants receive the same treatment without a control group. There is no masking involved, as it is an open-label study, and the primary purpose is to evaluate the treatment’s effectiveness.

The study began on March 21, 2024, with the most recent update submitted on September 25, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results that could impact future treatment options for gMG.

For investors, the ongoing development of CABA-201 could significantly influence Cabaletta Bio’s stock performance, especially if the results demonstrate positive outcomes. Given the competitive landscape of biopharmaceuticals targeting autoimmune diseases, successful trials could position Cabaletta Bio as a leader in innovative treatments for gMG.

The RESET-MG study is currently recruiting, with further details available on the ClinicalTrials portal.